2 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 2, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow CKD: new trials by email Literature Review of CKD trials Research Report on CKD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access Semaglutide, Virtual Weight Management Coaching - Obesity, Chronic Kidney Disease | Phase 4 | Not yet recruiting | Kristin Clemens | 880 | 2027-01-01 | 2026-10-05 |
| Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Empagliflozin 10 MG, Finerenone, Withings BPM Connect - Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2 | Phase 4 | Completed | University Medical Center Groningen | 12 | 2024-07-29 | 2026-02-13 |
| The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease Xiqing, probiotics - CKD, Drug Effect | Phase 4 | Recruiting | Chujin Cao | 120 | 2024-06-07 | 2025-09-19 |
| Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Dapagliflozin 10mg Tab, Placebo, Withings BPM Connect - Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria | Phase 4 | Completed | University Medical Center Groningen | 20 | 2021-05-11 | 2024-04-22 |
| Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease Ergocalciferol 50000 UNT, Placebo - CKD, Chronic Kidney Diseases | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2018-01-01 | 2018-03-15 | |
| Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Low dose erythropoietin, High dose erythropoietin - Anemia, CKD | Phase 4 | Terminated | VA Office of Research and Development | 5 | 2017-11-02 | 2020-08-13 |
Renal Insufficiency, Chronic (4) · Albuminuria (2) · Anemia (2) · Diabetes Complications (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Anemia, Iron-Deficiency (1) · Atherosclerosis (1) · Obesity (1) · Proteinuria (1)
Chronic Disease (4) · Disease Attributes (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Nutritional and Metabolic Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Renal Insufficiency (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Metabolic Diseases (3) · Signs and Symptoms (3) · Endocrine System Diseases (2)
Contraceptives, Oral (1) · Digital Technology (1) · Erythropoietin (1) · Micro-Electrical-Mechanical Systems (1) · Probiotics (1) · dapagliflozin (1) · empagliflozin (1) · finerenone (1) · semaglutide (1)
University Medical Center Groningen (2) · Chujin Cao (1) · Kristin Clemens (1) · University of Alabama at Birmingham (1) · VA Office of Research and Development (1)
Netherlands (2) · United States (2) · Canada (1) · China (1)
Hiddo Lambers Heerspink (1) · Kristin Clemens, MD (1) · Louise Moist, MD (1) · Mark S. Segal, MD PhD (1) · Ying Yao, PhD (1)
I01CX001449 (1)